A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19
Clinical trial NCT04582318 · TERMINATED
Trial details
- NCT number
- NCT04582318
- Sponsor
- NGM Biopharmaceuticals, Inc
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-09
- Primary completion
- 2021-02-18
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.